US38000Q1022 - Common Stock
GLYCOMIMETICS INC
NASDAQ:GLYC (4/25/2024, 3:00:12 PM)
1.71
-0.15 (-8.06%)
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 38 full-time employees. The company went IPO on 2014-01-10. The company is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. The company is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. The company has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The firm is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850
P: 12402431201
CEO: Rachel K. King
Employees: 38
Website: https://glycomimetics.com/
GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GlycoMimetics (NASDAQ:GLYC) just reported results for the fourth quarter of 202...
Here you can normally see the latest stock twits on GLYC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: